BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16785868)

  • 1. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria?
    Kelly M; Roy DC; Labbe AC; Laverdiere M
    Bone Marrow Transplant; 2006 Aug; 38(3):183-8. PubMed ID: 16785868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae.
    Klein MA; Kadidlo D; McCullough J; McKenna DH; Burns LJ
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1142-9. PubMed ID: 17085307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts.
    Kamble R; Pant S; Selby GB; Kharfan-Dabaja MA; Sethi S; Kratochvil K; Kohrt N; Ozer H
    Transfusion; 2005 Jun; 45(6):874-8. PubMed ID: 15934984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of pulsed-field gel electrophoresis to identify the source of bacterial contamination of peripheral blood progenitor cell products.
    Reich-Slotky R; Wu F; Della-Latta P; Savage DG; Schwartz J
    Transfusion; 2008 Nov; 48(11):2409-13. PubMed ID: 18657076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterility testing of hematopoietic progenitor cell products: a single-institution series of culture-positive rates and successful infusion of culture-positive products.
    Padley DJ; Dietz AB; Gastineau DA
    Transfusion; 2007 Apr; 47(4):636-43. PubMed ID: 17381622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts.
    Vanneaux V; Foïs E; Robin M; Rea D; de Latour RP; Biscay N; Chantre E; Robert I; Wargnier A; Traineau R; Benbunan M; Marolleau J; Socié G; Larghero J
    Cytotherapy; 2007; 9(5):508-13. PubMed ID: 17786612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbial contamination of harvested bone marrow and peripheral blood.
    Prince HM; Page SR; Keating A; Saragosa RF; Vukovic NM; Imrie KR; Crump M; Stewart AK
    Bone Marrow Transplant; 1995 Jan; 15(1):87-91. PubMed ID: 7742761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial contamination of autologous bone marrow: reinfusion of culture-positive grafts does not result in clinical sequelae during the posttransplantation course.
    Schwella N; Rick O; Heuft HG; Miksits K; Zimmermann R; Zingsem J; Eckstein R; Huhn D
    Vox Sang; 1998; 74(2):88-94. PubMed ID: 9501406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbial contamination of hematopoietic progenitor cell products: clinical outcome.
    Patah PA; Parmar S; McMannis J; Sadeghi T; Karandish S; Rondon G; Tarrand J; Champlin R; de Lima M; Shpall EJ
    Bone Marrow Transplant; 2007 Aug; 40(4):365-8. PubMed ID: 17572714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbial contamination of hematopoietic progenitor cell products.
    Namdaroğlu S; Tekgündüz E; Bozdağ SC; Durgun G; Sarıca A; Demiriz IŞ; Koçubaba S; Iskender G; Kayıkçı O; Altuntaş F
    Transfus Apher Sci; 2013 Jun; 48(3):403-6. PubMed ID: 23664302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous transplant: microbial contamination of hematopoietic stem cell products.
    Almeida ID; Schmalfuss T; Röhsig LM; Goldani LZ
    Braz J Infect Dis; 2012; 16(4):345-50. PubMed ID: 22846122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbial contamination of cellular products for hematolymphoid transplantation therapy: assessment of the problem and strategies to minimize the clinical impact.
    Lowder JN; Whelton P
    Cytotherapy; 2003; 5(5):377-90. PubMed ID: 14578100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.
    Del Pozo JL; Alonso M; Serrera A; Hernaez S; Aguinaga A; Leiva J
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):208-12. PubMed ID: 19026506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance.
    Mikulska M; Del Bono V; Raiola AM; Bruno B; Gualandi F; Occhini D; di Grazia C; Frassoni F; Bacigalupo A; Viscoli C
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):47-53. PubMed ID: 19135942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
    Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
    Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation.
    Slavin MA; Grigg AP; Schwarer AP; Szer J; Spencer A; Sainani A; Thursky KA; Roberts AW
    Bone Marrow Transplant; 2007 Jul; 40(2):157-63. PubMed ID: 17468774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial contamination of autologous peripheral blood stem cell products: incidence, clinical outcome, quality control and management strategies.
    Cheah PL; Ong CW; Crispin P
    Pathology; 2011 Jun; 43(4):340-5. PubMed ID: 21532522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of potential contaminants in blood cultures among patients in a medical center.
    Lee CC; Lin WJ; Shih HI; Wu CJ; Chen PL; Lee HC; Lee NY; Chang CM; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2007 Oct; 40(5):438-44. PubMed ID: 17932605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.